Abstract

Lung cancer represents the most common cause of cancer related deaths in both men and women with 177,000 cases diagnosed in 1996 and 158,000 deaths. Most patients present with advanced disease and aggressive therapy has been able to change their outcome only modestly. In most centers, primary radiation alone has been replaced by multimodality therapy. The simultaneous combination of chemotherapy and radiotherapy theoretically may provide a better effect on response rates and local control compared to a sequential schedule. Cisplatin is thought to be one of the active drugs in non-small cell lung cancer with a 15-20% response rate. In addition, Cisplatin is considered a radiosensitizer when administered with radiation therapy. Docetaxel is also known to act as a radiosensitizer, and several trials have reported their early results with suggestion of a potential benefit.
The aims of this study are: to determine the maximal tolerated dose of Docetaxel in combination with Cisplatin and concomitant radiation therapy in the phase I component; to determine the safety and tolerability of the same combination once the maximal tolerated dose Docetaxel has been determined; and to determine the response rate, median survival and time to progression of patients with clinical stage IIIA and IIIB NSCLC with this combination.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR005096-11
Application #
6411344
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1990-01-14
Project End
2001-11-30
Budget Start
Budget End
Support Year
11
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Tulane University
Department
Type
DUNS #
City
New Orleans
State
LA
Country
United States
Zip Code
70118

  Publications

Allegrezza, Michael J; Rutkowski, Melanie R; Stephen, Tom L et al. (2016) Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. Cancer Res 76:6253-6265
Drerup, Justin M; Liu, Yang; Padron, Alvaro S et al. (2015) Immunotherapy for ovarian cancer. Curr Treat Options Oncol 16:317
Chyun, Deborah A; Wackers, Frans J Th; Inzucchi, Silvio E et al. (2015) Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Med 3:2050312114568476
Rahman, Mahboob; Xie, Dawei; Feldman, Harold I et al. (2014) Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study. Am J Nephrol 40:399-407
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Ricardo, Ana C; Yang, Wei; Lora, Claudia M et al. (2014) Limited health literacy is associated with low glomerular filtration in the Chronic Renal Insufficiency Cohort (CRIC) study. Clin Nephrol 81:30-7
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Wing, Maria R; Devaney, Joseph M; Joffe, Marshall M et al. (2014) DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study. Nephrol Dial Transplant 29:864-72
Mariani, Laura H; White, Matthew T; Shults, Justine et al. (2014) Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study. J Ren Nutr 24:186-93
Wing, Maria R; Yang, Wei; Teal, Valerie et al. (2014) Race modifies the association between adiposity and inflammation in patients with chronic kidney disease: findings from the chronic renal insufficiency cohort study. Obesity (Silver Spring) 22:1359-66

Showing the most recent 10 out of 211 publications